Developer · United States
Autobahn Therapeutics, Inc.
Autobahn Therapeutics is a privately held San Diego biotechnology company developing small-molecule therapies for neuropsychiatric and neuroimmunologic disorders using its brain-targeting chemistry platform. Its lead program, elunetirom (ABX-002), is a CNS-directed thyroid hormone receptor agonist in Phase 2 development for bipolar depression and major depressive disorder.
Pipeline (1)
- Bipolar depressionPhase 2Active
- Major depressive disorderPhase 2Recruiting
Catalysts · 1 upcoming · 1 reported
- Q3 2026Anticipated
Elunetirom (ABX-002)forMajor depressive disorderTopline data
AMPLIFY Phase 2 topline (adjunctive MDD): HAMD-17 change at Week 6 vs. placebo, expected Q3 2026.
Recently reported
- 2026-06-04met
Elunetirom (ABX-002)forBipolar depressionTopline data
AMPLIFY-BD met its primary endpoint: HAMD-17 -16.8 at Week 6 (p<0.001), 75% response, 50% remission in adjunctive bipolar depression.
Recent activity
- Jun 4, 2026ReadoutElunetirom (ABX-002)·Bipolar depressionmetAMPLIFY-BD met its primary endpoint: HAMD-17 -16.8 at Week 6 (p<0.001), 75% response, 50% remission in adjunctive bipolar depression.source ↗
- Jan 8, 2025Phase changeElunetirom (ABX-002)·Bipolar depressionPhase 2Autobahn announced initiation of the open-label Phase 2 bipolar depression trial (AMPLIFY-BD); ClinicalTrials.gov records an actual start date of 28 Mar 2025.source ↗
- Oct 22, 2024Phase changeElunetirom (ABX-002)·Bipolar depressionPhase 2FDA cleared the IND for ABX-002 as an adjunctive treatment for bipolar depression; company planned to begin the Phase 2 trial by year-end 2024.source ↗
- Sep 16, 2024Phase changeElunetirom (ABX-002)·Major depressive disorderPhase 2Autobahn announced initiation of the AMPLIFY Phase 2 trial of ABX-002 as an adjunctive treatment for major depressive disorder (randomized, double-blind, placebo-controlled, ~230 patients, 6-week HAMD-17 primary endpoint). ClinicalTrials.gov records an actual start date of 20 Sep 2024.source ↗
Trials recruiting · 1 recruiting of 2 sponsored
- Phase 2Elunetirom (ABX-002)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Competitive landscape
Other companies developing against Autobahn Therapeutics, Inc.'s targets or indications.
- Alto Neuroscience, Inc.3 compoundsBipolar depressionMajor depressive disorder
- Intra-Cellular Therapies, Inc.1 compoundBipolar depressionMajor depressive disorder
- LB Pharmaceuticals Inc.1 compoundBipolar depressionMajor depressive disorder
- Xenon Pharmaceuticals Inc.1 compoundBipolar depressionMajor depressive disorder
- Axsome Therapeutics, Inc.1 compoundMajor depressive disorder
- Beckley Psytech Limited1 compoundMajor depressive disorder
- Biohaven Ltd.1 compoundMajor depressive disorder
- Boehringer Ingelheim International GmbH2 compoundsMajor depressive disorder
- Cerevel Therapeutics Holdings, Inc.1 compoundMajor depressive disorder
- COMPASS Pathways plc1 compoundMajor depressive disorder
- CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.1 compoundMajor depressive disorder
- Definium Therapeutics, Inc.1 compoundMajor depressive disorder
